

## Total Voting Rights

**Hong Kong, Shanghai, & Florham Park, NJ — Friday, April 28, 2023:** HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) hereby notifies the market that as at April 28, 2023, the issued share capital of HUTCHMED consisted of 866,131,390 ordinary shares of US\$0.10 each, with each share carrying one right to vote and with no shares held in treasury.

The above figure of 866,131,390 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For illustrative purposes only, the 866,131,390 ordinary shares would be equivalent to 866,131,390 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 173,226,278 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.

### About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception, HUTCHMED has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: [www.hutchmed.com](http://www.hutchmed.com) or follow us on [LinkedIn](https://www.linkedin.com/company/hutchmed).

### Contacts

#### Investor Enquiries

Mark Lee, Senior Vice President	+852 2121 8200
Annie Cheng, Vice President	+1 (973) 306-4490

#### Media Enquiries

<b>Americas</b> – Brad Miles, Solebury Strategic Communications	+1 (917) 570 7340 (Mobile) / <a href="mailto:bmiles@soleburystrat.com">bmiles@soleburystrat.com</a>
<b>Europe</b> – Ben Atwell / Alex Shaw, FTI Consulting	+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) <a href="mailto:HUTCHMED@fticonsulting.com">HUTCHMED@fticonsulting.com</a>
<b>Asia</b> – Zhou Yi, Brunswick	+852 9783 6894 (Mobile) / <a href="mailto:HUTCHMED@brunswickgroup.com">HUTCHMED@brunswickgroup.com</a>

#### Nominated Advisor

Atholl Tweedie / Freddy Crossley, Panmure Gordon	+44 (20) 7886 2500
--	--------------------

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRZZGZDGNDGFZM